Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Randomized Phase III Trial of Local Consolidation Therapy (LCT) After Nivolumab and Ipilimumab for Immunotherapy-Naive Patients With Metastatic Non-Small Cell Lung Cancer (LONESTAR) -Strategic Alliance: BMS

Trial Profile

Randomized Phase III Trial of Local Consolidation Therapy (LCT) After Nivolumab and Ipilimumab for Immunotherapy-Naive Patients With Metastatic Non-Small Cell Lung Cancer (LONESTAR) -Strategic Alliance: BMS

Recruiting
Phase of Trial: Phase III

Latest Information Update: 16 Nov 2018

At a glance

  • Drugs Ipilimumab (Primary) ; Nivolumab (Primary)
  • Indications Non-small cell lung cancer
  • Focus Therapeutic Use
  • Acronyms LONESTAR
  • Most Recent Events

    • 02 Nov 2018 Planned End Date changed from 1 Dec 2023 to 1 Dec 2022.
    • 07 Feb 2018 Planned End Date changed from 1 Dec 2022 to 1 Dec 2023.
    • 08 Jan 2018 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top